This Title All WIREs
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 7.689

Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood–brain barrier

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract The major problem in drug delivery to the brain is the presence of the blood–brain barrier (BBB) which limits drug penetration even if in certain pathological situations the BBB is partly disrupted. Among noninvasive techniques to overcome this barrier, the use of nanoparticles has been proposed. This review focuses on poly(alkylcyanoacrylates) (PACA)‐based nanoparticles which have been developed for brain targeting. Both types of ‘stealth’ PACA nanoparticles with modified surface, those coated with surfactant and those with chains of polyethylene glycol (PEG) linked to the hydrophobic core of PACA are presented. The synthesis of polymers, the preparation of nanoparticles with modified surface and their physicochemical characterization are described. The review of their in vivo results evidenced their ability to enter into the brain using healthy animals or models of central nervous system (CNS) diseases. The nature of the surface modification (surfactant nature, PEG linkage, drug loading interference) seems to have a great influence on the efficacy of brain targeting which can be related to the adsorption of some apolipoproteins (Apo E, B, A‐I). The mechanism of their passage through the BBB has been studied by in vitro and in vivo experiments, which suggested the implication of receptor‐mediated endocytosis processes. According to these data, some antibodies (OX26) and ligands (transferrin, Apo E/B/A‐I) seem to be good candidates to be coupled with ‘stealth’ PACA nanoparticles in order to increase their passage through the BBB and to promote active targeting to the brain Copyright © 2009 John Wiley & Sons, Inc. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease

Structures of (a) Poly(butylcyanoacrylate) (PBCA), (b) PHDCA polymers, and (c) PEG‐PHDCA copolymer.

[ Normal View | Magnified View ]

Potential mechanism scheme of the endothelial cell uptake after IV injection of stealth poly(alkylcyanoacrylates) (PACA) nanoparticles.

[ Normal View | Magnified View ]

Schematic representation of stealth poly(alkylcyanoacrylates) (PACA) nanoparticles developed for brain targeting: (a) PS80 coated‐Poly(butylcyanoacrylate) (PBCA) nanoparticles, (b) PEG‐PHDCA nanoparticles.

[ Normal View | Magnified View ]

Scheme of the degradation process of poly(alkylcyanoacrylates) (PACA) polymers by esterases.

[ Normal View | Magnified View ]

Browse by Topic

Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts